Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EBT (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported EBT over the past 12 years, most recently at -$118.2 million for Q4 2025.

  • Quarterly results put EBT at -$118.2 million for Q4 2025, down 48.79% from a year ago — trailing twelve months through Dec 2025 was -$340.9 million (down 26.51% YoY), and the annual figure for FY2025 was -$340.9 million, down 26.45%.
  • EBT for Q4 2025 was -$118.2 million at Viridian Therapeutics, Inc.\DE, down from -$35.1 million in the prior quarter.
  • Over the last five years, EBT for VRDN hit a ceiling of -$14.0 million in Q3 2021 and a floor of -$118.2 million in Q4 2025.
  • Median EBT over the past 5 years was -$48.1 million (2023), compared with a mean of -$52.9 million.
  • Peak annual rise in EBT hit 68.11% in 2021, while the deepest fall reached 177.74% in 2021.
  • Viridian Therapeutics, Inc.\DE's EBT stood at -$28.9 million in 2021, then crashed by 58.17% to -$45.8 million in 2022, then crashed by 45.61% to -$66.7 million in 2023, then fell by 19.2% to -$79.5 million in 2024, then plummeted by 48.79% to -$118.2 million in 2025.
  • The last three reported values for EBT were -$118.2 million (Q4 2025), -$35.1 million (Q3 2025), and -$100.7 million (Q2 2025) per Business Quant data.